Sec Form 4 Filing - BLATT LAWRENCE @ Aligos Therapeutics, Inc. - 2020-10-20

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person BLATT LAWRENCE 2. Issuer Name and Ticker or Trading Symbol Aligos Therapeutics, Inc. [ ALGS] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Executive Officer (Last) (First) (Middle) C/O ALIGOS THERAPEUTICS, INC., 1 CORPORATE DRIVE, 2ND FLOOR 3. Date of Earliest Transaction (MM/DD/YY) 10/20/2020 (Street) SOUTH SAN FRANCISCO, CA94080 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 1,237,298 D Common Stock 10/20/2020 C 41,016 A 41,016 I See footnote ( 2 ) Common Stock 10/20/2020 C 122,601 A 122,601 I See footnote ( 3 ) Common Stock 10/20/2020 C 13,671 A 13,671 I See footnote ( 4 ) Common Stock 10/20/2020 C 13,671 A 13,671 I See footnote ( 5 ) Common Stock 10/20/2020 C 50,712 A 91,728 I See footnote ( 2 ) Common Stock 10/20/2020 C 3,394 A 17,065 I See footnote ( 4 ) Common Stock 10/20/2020 C 3,394 A 17,065 I See footnote ( 5 ) Common Stock 10/20/2020 C 21,695 A 113,423 I See footnote ( 2 ) Common Stock 10/20/2020 C 1,452 A 18,517 I See footnote ( 4 ) Common Stock 10/20/2020 C 1,452 A 18,517 I See footnote ( 5 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series A Preferred Stock ( 1 ) 10/20/2020 C 41,016 ( 1 ) ( 1 ) Common Stock 41,016 $ 0 0 I See footnote ( 2 ) Series A Preferred Stock ( 1 ) 10/20/2020 C 122,601 ( 1 ) ( 1 ) Common Stock 122,601 $ 0 0 I See footnote ( 3 ) Series A Preferred Stock ( 1 ) 10/20/2020 C 13,671 ( 1 ) ( 1 ) Common Stock 13,671 $ 0 0 I See footnote ( 4 ) Series A Preferred Stock ( 1 ) 10/20/2020 C 13,671 ( 1 ) ( 1 ) Common Stock 13,671 $ 0 0 I See footnote ( 5 ) Series B-1 Preferred Stock ( 1 ) 10/20/2020 C 50,712 ( 1 ) ( 1 ) Common Stock 50,712 $ 0 0 I See footnote ( 2 ) Series B-1 Preferred Stock ( 1 ) 10/20/2020 C 3,394 ( 1 ) ( 1 ) Common Stock 3,394 $ 0 0 I See footnote ( 4 ) Series B-1 Preferred Stock ( 1 ) 10/20/2020 C 3,394 ( 1 ) ( 1 ) Common Stock 3,394 $ 0 0 I See footnote ( 5 ) Series B-2 Preferred Stock ( 1 ) 10/20/2020 C 21,695 ( 1 ) ( 1 ) Common Stock 21,695 $ 0 0 I See footnote ( 2 ) Series B-2 Preferred Stock ( 1 ) 10/20/2020 C 1,452 ( 1 ) ( 1 ) Common Stock 1,452 $ 0 0 I See footnote ( 4 ) Series B-2 Preferred Stock ( 1 ) 10/20/2020 C 1,452 ( 1 ) ( 1 ) Common Stock 1,452 $ 0 0 I See footnote ( 5 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other BLATT LAWRENCE C/O ALIGOS THERAPEUTICS, INC. 1 CORPORATE DRIVE, 2ND FLOOR SOUTH SAN FRANCISCO, CA94080 Chief Executive Officer Signatures /s/ Lucinda Y. Quan, as attorney-in fact for Lawrence M. Blatt 10/20/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. ( 2 )Lawrence M. Blatt Living Trust dated 8/27/14. ( 3 )PENSCO Trust Company LLC Custodian FBO Dr. Lawrence Blatt IRA ( 4 )Zachary David Blatt Irrevocable Trust dated 8/24/14. ( 5 )Zoe Anne Blatt Irrevocable Trust dated 8/24/14.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.